However, considering previous studies have shown that AChE inhibition of 65% or higher is associated with improvement in Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) scores, the level of inhibition observed in this study was approximately 37%, and this degree of inhibition was insufficient to clearly infer clinical efficacy [18]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.